The results of the landmark CURE study, conducted on a broad spectrum of patients with Acute Coronary Syndrome (ACS), have demonstrated that a therapeutic approach based on the dual antiplatelet combination of Aspirin and Clopidogrel provides superior protection compared to Aspirin monotherapy.
According to the study, the use of DIOPIRAVIN (the effective combination of Aspirin and Clopidogrel) contributed to:
Reducing the risk of myocardial infarction, stroke, and cardiovascular death by 20% compared to the use of Aspirin alone.
At Ibn Al-Haytham, we are committed to providing evidence-based pharmaceutical solutions to ensure the highest standards of safety and efficacy for patients.
To access the full details of the clinical study, you can visit the JAMA Network website via the following link:
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/215618?utm_source=chatgpt.com